Rapid diagnosis of drug-resistant TB using line probe assays: From evidence to policy

Expert Review of Respiratory Medicine

Volumn 2, Issue 5, 2008, Pages 583-588

  Ling, Daphne I ^a   Zwerling, Alice A ^a   Pai, Madhukar ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Diagnostic accuracy; Extensively drug resistant TB; Line probe assays; MDR TB; Multidrug resistant TB; TB; Tuberculosis; XDR TB

Indexed keywords

AMIKACIN; CAPREOMYCIN; ISONIAZID; KANAMYCIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM CULTURE; BIOASSAY; COST CONTROL; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; GENE MUTATION; HEALTH CARE COST; HEALTH CARE POLICY; HIGH RISK POPULATION; HUMAN; INCIDENCE; INFECTION RISK; LINE PROBE ASSAY; LUNG TUBERCULOSIS; MULTIDRUG RESISTANCE; PREVALENCE; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SPUTUM CULTURE;

EID: 55149084546     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/17476348.2.5.583     Document Type: Article

References (12)

1. World Health Organization. Global tuberculosis control. Surveillance, planning, financing. WHO Report 2007. WHO/HTM/TB/2007.376. World Health Organization, Geneva, Switzerland, 1-242 (2007).
2. World Health Organization. The Global MDR-TB and XDR-TB Response Plan, 2007-2008. WHO/HTM/TB/2007.387. World Health Organization, Geneva, Switzerland (2007).
3. Zignol M, Hosseini MS, Wright A et al. Global incidence of multidrug-resistant tuberculosis. J. Infect. Dis. 194(4), 479-485 (2006).
4. Migliori GB, Matteelli A, Cirillo D, Pai M. Diagnosis of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: current standards and challenges. Can. J. Infect. Dis. Med. Microbiol. 19(2), 169-172 (2008).
5. Pai M, Kalantri S, Dheda K. New tools and emerging technologies for the diagnosis of tuberculosis: part 2. Active tuberculosis and drug resistance. Expert Rev. Mol. Diagn. 6(3), 423-432 (2006).
6. Migliori GB, Loddenkemper R, Blasi F, Raviglione MC. 125 years after Robert Koch's discovery of the tubercle bacillus: the new XDR-TB threat. Is "science" enough to tackle the epidemic? Eur. Respir. J. 29(3), 423-427 (2007).
7. Perkins MD, Cunningham J. Facing the crisis: improving the diagnosis of tuberculosis in the HIV era. J. Infect. Dis. 196(Suppl. 1), S15-S27 (2007).
8. Morgan M, Kalantri S, Flores L, Pai M. A commercial line probe assay for the rapid detection of rifampicin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. BMC Infect. Dis. 5, 62 (2005).
9. Ling DI, Zwerling A, Pai M. GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis. Eur. Respir. J. DOI 10.1183/09031936.00061808 (2008)
10. Barnard M, Albert H, Coetzee G, O'Brien R, Bosman ME. Rapid molecular screening for MDR TB in a high volume public health laboratory in South Africa. Am. J. Respir. Crit. Care Med. (2008).
11. Kim SJ. Drug-susceptibility testing in tuberculosis: methods and reliability of results. Eur. Respir. J. 25(3), 564-569 (2005).
12. Pai M, Ramsay A, O'Brien R. Evidence-based tuberculosis diagnosis. PLoS Med. 5(7), e156 (2008).